Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Controlled Exploratory Trial for Treatment of Fibrosing Interstitial Lung Disease Patients Secondary to SARS-CoV-2 Infection With IN01 Vaccine (COVINVAC)

NCT04537130 is registered in ClinicalTrials.gov with Instituto Oncológico Dr Rosell as lead sponsor.

NCT NCT04537130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04537130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Controlled Exploratory Trial for Treatment of Fibrosing Interstitial Lung Disease Patients Secondary to SARS-CoV-2 Infection With IN01 Vaccine (COVINVAC)
Lead sponsor
Instituto Oncológico Dr Rosell
Phase
Phase 1
Overall status
Unknown status
Start date
December 1, 2020
Completion date
June 30, 2022
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, pulmonary fibrosis